Literature DB >> 7265922

Isolation and identification of a metabolite of haloperidol.

B E Pape.   

Abstract

A new metabolite of haloperidol, formed by what is equivalent to the reduction of the carbonyl group to the alcohol, has been identified in human serum, liver and urine. The isolation and chromatographic behavior of the compound are discussed.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7265922     DOI： 10.1093/jat/5.3.113

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN： 0146-4760            Impact factor:   3.367


  9 in total

1.  Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients.

Authors:  H K Roh; J Y Chung; D Y Oh; C S Park; J O Svensson; M L Dahl; L Bertilsson
Journal:  Br J Clin Pharmacol       Date:  2001-09       Impact factor: 4.335

Review 2.  Pharmacokinetics of haloperidol: an update.

Authors:  S Kudo; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

3.  Interconversion between haloperidol and reduced haloperidol in healthy volunteers.

Authors:  B S Chakraborty; J W Hubbard; E M Hawes; G McKay; J K Cooper; T Gurnsey; E D Korchinski; K K Midha
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 4.  Clinical pharmacokinetics of the depot antipsychotics.

Authors:  M W Jann; L Ereshefsky; S R Saklad
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

5.  Reversible metabolism of haloperidol and reduced haloperidol in Chinese schizophrenic patients.

Authors:  M W Jann; Y W Lam; W H Chang
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

6.  Synthesis of the enantiomers of reduced haloperidol.

Authors:  J C Jaen; B W Caprathe; S Priebe; L D Wise
Journal:  Pharm Res       Date:  1991-08       Impact factor: 4.200

7.  Effect of quinidine on the interconversion kinetics between haloperidol and reduced haloperidol in humans: implications for the involvement of cytochrome P450IID6.

Authors:  D Young; K K Midha; M J Fossler; E M Hawes; J W Hubbard; G McKay; E D Korchinski
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

8.  Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase).

Authors:  R F Tyndale; W Kalow; T Inaba
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

Review 9.  Pharmacokinetics of haloperidol.

Authors:  J S Froemming; Y W Lam; M W Jann; C M Davis
Journal:  Clin Pharmacokinet       Date:  1989-12       Impact factor: 6.447
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.